Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porseelin with radiotherapy for postoperative primary high-grade spinal cord glioma
CTR20234234Phase 2Active
- Sponsor
- Shanghai Yuanxi Medical Technology
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in diffuse midline glioma (DMG), sponsored by Shanghai Yuanxi Medical Technology. Started Apr 2024; status: active.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on CTR20234234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234234.